Molecular Partners Initiates Phase 1/2a Trial for MP0712, First Patient Dosing Expected Q1 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 11 2026
0mins
Should l Buy MOLN?
Source: Yahoo Finance
- Trial Initiation: Molecular Partners has initiated a Phase 1/2a clinical trial for MP0712 in the US, with first patient dosing expected in Q1 2026, aimed at assessing safety and determining the recommended dose, thereby positioning the company as a leader in targeted radiotherapy for small cell lung cancer.
- Cash Position: As of December 31, 2025, the company reported cash and cash equivalents of CHF 93.1 million, which is projected to fund operating expenses and capital expenditures until 2028, ensuring financial stability for the coming years.
- Drug Development Progress: The Phase 2 trial for MP0317 is now open, aiming to recruit 75 patients to evaluate the clinical benefits of its combination with standard care, further advancing the company's innovation in cholangiocarcinoma treatment.
- Scientific Advisory Board Formation: The establishment of a scientific advisory board in December 2025 aims to accelerate the development of targeted radiotherapeutics, demonstrating the company's strategic commitment to transitioning from clinical validation to full clinical development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MOLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MOLN
Wall Street analysts forecast MOLN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.930
Low
8.00
Averages
10.00
High
12.00
Current: 3.930
Low
8.00
Averages
10.00
High
12.00
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Molecular Partners Reports FY 2025 Financial Results with Significant Losses
- Revenue and Loss Overview: Molecular Partners reported no revenue for FY 2025, down from CHF 5 million in 2024, resulting in an operating loss of CHF 58.1 million, although this represents an improvement from CHF 61.2 million in 2024, indicating efforts in cost management.
- Net Financial Loss: The company recorded a net financial loss of CHF 3.5 million in 2025, contrasting sharply with a net financial gain of CHF 7.2 million in 2024, highlighting significant financial challenges that may impact future funding capabilities.
- Cash Flow and Asset Status: As of December 31, 2025, cash and cash equivalents decreased to CHF 93.1 million, down CHF 56.3 million from the end of 2024, reflecting ongoing cash outflow pressures, although it is projected to sustain operations until 2028.
- Employee and R&D Investment: The company employed 134 full-time equivalents as of 2025, with 81% engaged in R&D functions, demonstrating a commitment to innovation despite financial hurdles, indicating a strategic focus on long-term technological advancements.
See More
Molecular Partners Initiates DLL3-Targeting Study for SCLC
- Clinical Trial Launch: Molecular Partners, in collaboration with Orano Med, has initiated a Phase 1/2a clinical trial for MP0712 targeting DLL3 in the US, aimed at treating small cell lung cancer (SCLC) and other neuroendocrine cancers, with initial data expected in 2026, indicating significant progress in targeted radiotherapy.
- Strong Financial Position: As of December 31, 2025, the company reported cash and short-term deposits totaling CHF 93.1 million, providing a runway until 2028, demonstrating financial stability for ongoing R&D and clinical trials.
- New Drug Candidate Progress: The second Radio-DARPin candidate, MP0726, is advancing towards first-in-human imaging, with new candidates expected to be nominated by mid-2026, showcasing the company's ongoing innovation in multi-target therapies.
- R&D Collaboration Agreement: The development agreement with Eckert & Ziegler will support Radio-DARPin candidates with various isotopes, further enhancing the company's R&D pipeline and indicating a strategic focus on radiopharmaceutical development.
See More
Molecular Partners to Release Full-Year 2025 Financial Report
- Investor Conference Schedule: Molecular Partners will attend the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, where CEO Patrick Amstutz will participate in a fireside chat on March 2 from 2:30 to 3:00 PM ET, aiming to attract potential investors by showcasing the company's latest advancements in biotechnology.
- Financial Report Release: The company plans to issue its full-year 2025 financial report on March 12, 2026, at 4:00 PM, providing detailed financial data and business developments that will help investors assess the company's financial health and future growth potential.
- Multiple Conference Participation: In addition to the TD Cowen conference, Molecular Partners will also present at the Leerink Partners Global Healthcare Conference from March 9-11, 2026, further enhancing the company's visibility and influence within the industry.
- Cautionary Note on Forward-Looking Statements: The press release includes forward-looking statements regarding clinical development and financial outlook, highlighting potential risks and uncertainties, and reminding investors to consider factors that may impact the company's future performance.
See More
Significant Progress in MP0712 Clinical Development
- Clinical Data Support: At the 8th Theranostics World Congress in South Africa, Molecular Partners presented initial imaging and dosimetry data for MP0712, strongly supporting clinical development plans for small cell lung cancer and other DLL3-expressing cancers.
- Tumor Uptake Performance: MP0712 demonstrated significant uptake in tumor lesions with a favorable biodistribution profile, showing low uptake in healthy tissues, indicating its potential therapeutic advantages.
- U.S. Study Launch: The Phase 1/2a study of MP0712 has commenced in the U.S., with initial clinical data expected in 2026, further validating its efficacy in treating small cell lung cancer.
- Strengthened Strategic Collaboration: The partnership between Molecular Partners and Orano Med enhances the development of MP0712, aiming to leverage its unique Radio-DARPin platform to improve the efficacy of targeted radiopharmaceuticals and strengthen its competitive position in tumor-targeted therapies.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Visa Rating Upgrade: Cantor Fitzgerald analyst Ramsey El-Assal initiated coverage on Visa Inc (NYSE:V) with an Overweight rating and a price target of $400, indicating significant upside from Monday's closing price of $328.49, reflecting confidence in its future growth.
- Intuitive Surgical New Rating: TD Cowen analyst Mathew Blackman initiated coverage on Intuitive Surgical Inc (NASDAQ:ISRG) with a Buy rating and a price target of $660, which, compared to its Monday closing price of $528.81, highlights market recognition of its innovative technologies.
- Molecular Partners Buy Rating: HC Wainwright & Co. analyst Robert Burns initiated coverage on Molecular Partners AG (NASDAQ:MOLN) with a Buy rating and a price target of $13, representing significant upside from its Monday closing price of $4.00, indicating optimistic market expectations regarding its R&D progress.
- Mastercard Rating Upgrade: Cantor Fitzgerald analyst Ramsey El-Assal initiated coverage on Mastercard Inc (NYSE:MA) with an Overweight rating and a price target of $650, showing a positive outlook based on its Monday closing price of $527.36, reflecting confidence in its market performance.
See More
Molecular Partners Initiates MP0712 Clinical Trial, First Patient Dosing Expected Q1 2026
- Clinical Trial Launch: Molecular Partners has initiated a Phase 1/2a clinical trial for MP0712 in the US, with first patient dosing expected in Q1 2026, aiming to assess safety and determine the recommended dose, thereby enhancing the company's leadership in targeted radiotherapy.
- Strong Cash Position: As of December 31, 2025, the company reported cash and cash equivalents of CHF 93.1 million, which is projected to fund operating expenses and capital expenditures until 2028, ensuring the company's capacity for R&D and market expansion in the coming years.
- New Drug Development Progress: The Phase 2 trial for MP0317 is now open, targeting 75 patients to evaluate the clinical benefits of its combination with standard care, thereby strengthening the company's competitive position in cholangiocarcinoma treatment.
- Multi-Target Therapy: The Phase 1/2a trial for MP0533 is ongoing, with preliminary data indicating good tolerability and antitumor activity in acute myeloid leukemia patients, with an update on the clinical development path expected in H1 2026, further solidifying the company's product pipeline.
See More
Molecular Partners Reports FY 2025 Financial Results with Significant Losses
- Revenue and Loss Overview: Molecular Partners reported no revenue for FY 2025, down from CHF 5 million in 2024, resulting in an operating loss of CHF 58.1 million, although this represents an improvement from CHF 61.2 million in 2024, indicating efforts in cost management.
- Net Financial Loss: The company recorded a net financial loss of CHF 3.5 million in 2025, contrasting sharply with a net financial gain of CHF 7.2 million in 2024, highlighting significant financial challenges that may impact future funding capabilities.
- Cash Flow and Asset Status: As of December 31, 2025, cash and cash equivalents decreased to CHF 93.1 million, down CHF 56.3 million from the end of 2024, reflecting ongoing cash outflow pressures, although it is projected to sustain operations until 2028.
- Employee and R&D Investment: The company employed 134 full-time equivalents as of 2025, with 81% engaged in R&D functions, demonstrating a commitment to innovation despite financial hurdles, indicating a strategic focus on long-term technological advancements.
See More
Molecular Partners Initiates DLL3-Targeting Study for SCLC
- Clinical Trial Launch: Molecular Partners, in collaboration with Orano Med, has initiated a Phase 1/2a clinical trial for MP0712 targeting DLL3 in the US, aimed at treating small cell lung cancer (SCLC) and other neuroendocrine cancers, with initial data expected in 2026, indicating significant progress in targeted radiotherapy.
- Strong Financial Position: As of December 31, 2025, the company reported cash and short-term deposits totaling CHF 93.1 million, providing a runway until 2028, demonstrating financial stability for ongoing R&D and clinical trials.
- New Drug Candidate Progress: The second Radio-DARPin candidate, MP0726, is advancing towards first-in-human imaging, with new candidates expected to be nominated by mid-2026, showcasing the company's ongoing innovation in multi-target therapies.
- R&D Collaboration Agreement: The development agreement with Eckert & Ziegler will support Radio-DARPin candidates with various isotopes, further enhancing the company's R&D pipeline and indicating a strategic focus on radiopharmaceutical development.
See More
Molecular Partners to Release Full-Year 2025 Financial Report
- Investor Conference Schedule: Molecular Partners will attend the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, where CEO Patrick Amstutz will participate in a fireside chat on March 2 from 2:30 to 3:00 PM ET, aiming to attract potential investors by showcasing the company's latest advancements in biotechnology.
- Financial Report Release: The company plans to issue its full-year 2025 financial report on March 12, 2026, at 4:00 PM, providing detailed financial data and business developments that will help investors assess the company's financial health and future growth potential.
- Multiple Conference Participation: In addition to the TD Cowen conference, Molecular Partners will also present at the Leerink Partners Global Healthcare Conference from March 9-11, 2026, further enhancing the company's visibility and influence within the industry.
- Cautionary Note on Forward-Looking Statements: The press release includes forward-looking statements regarding clinical development and financial outlook, highlighting potential risks and uncertainties, and reminding investors to consider factors that may impact the company's future performance.
See More
Significant Progress in MP0712 Clinical Development
- Clinical Data Support: At the 8th Theranostics World Congress in South Africa, Molecular Partners presented initial imaging and dosimetry data for MP0712, strongly supporting clinical development plans for small cell lung cancer and other DLL3-expressing cancers.
- Tumor Uptake Performance: MP0712 demonstrated significant uptake in tumor lesions with a favorable biodistribution profile, showing low uptake in healthy tissues, indicating its potential therapeutic advantages.
- U.S. Study Launch: The Phase 1/2a study of MP0712 has commenced in the U.S., with initial clinical data expected in 2026, further validating its efficacy in treating small cell lung cancer.
- Strengthened Strategic Collaboration: The partnership between Molecular Partners and Orano Med enhances the development of MP0712, aiming to leverage its unique Radio-DARPin platform to improve the efficacy of targeted radiopharmaceuticals and strengthen its competitive position in tumor-targeted therapies.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Visa Rating Upgrade: Cantor Fitzgerald analyst Ramsey El-Assal initiated coverage on Visa Inc (NYSE:V) with an Overweight rating and a price target of $400, indicating significant upside from Monday's closing price of $328.49, reflecting confidence in its future growth.
- Intuitive Surgical New Rating: TD Cowen analyst Mathew Blackman initiated coverage on Intuitive Surgical Inc (NASDAQ:ISRG) with a Buy rating and a price target of $660, which, compared to its Monday closing price of $528.81, highlights market recognition of its innovative technologies.
- Molecular Partners Buy Rating: HC Wainwright & Co. analyst Robert Burns initiated coverage on Molecular Partners AG (NASDAQ:MOLN) with a Buy rating and a price target of $13, representing significant upside from its Monday closing price of $4.00, indicating optimistic market expectations regarding its R&D progress.
- Mastercard Rating Upgrade: Cantor Fitzgerald analyst Ramsey El-Assal initiated coverage on Mastercard Inc (NYSE:MA) with an Overweight rating and a price target of $650, showing a positive outlook based on its Monday closing price of $527.36, reflecting confidence in its market performance.
See More
Molecular Partners Initiates MP0712 Clinical Trial, First Patient Dosing Expected Q1 2026
- Clinical Trial Launch: Molecular Partners has initiated a Phase 1/2a clinical trial for MP0712 in the US, with first patient dosing expected in Q1 2026, aiming to assess safety and determine the recommended dose, thereby enhancing the company's leadership in targeted radiotherapy.
- Strong Cash Position: As of December 31, 2025, the company reported cash and cash equivalents of CHF 93.1 million, which is projected to fund operating expenses and capital expenditures until 2028, ensuring the company's capacity for R&D and market expansion in the coming years.
- New Drug Development Progress: The Phase 2 trial for MP0317 is now open, targeting 75 patients to evaluate the clinical benefits of its combination with standard care, thereby strengthening the company's competitive position in cholangiocarcinoma treatment.
- Multi-Target Therapy: The Phase 1/2a trial for MP0533 is ongoing, with preliminary data indicating good tolerability and antitumor activity in acute myeloid leukemia patients, with an update on the clinical development path expected in H1 2026, further solidifying the company's product pipeline.
See More
